Literature DB >> 9882297

Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas.

G Habeshaw1, Q Y Yao, A I Bell, D Morton, A B Rickinson.   

Abstract

The Epstein-Barr virus (EBV) nuclear antigen EBNA1 is the only viral protein detectably expressed in virus genome-positive Burkitt's lymphoma (BL); recent work has suggested that viral strains with particular EBNA1 sequence changes are preferentially associated with this tumor and that, within a patient, the tumor-associated variant may have arisen de novo as a rare mutant of the dominant preexisting EBV strain (K. Bhatia, A. Raj, M. J. Gutierrez, J. G. Judde, G. Spangler, H. Venkatesh, and I. T. Magrath, Oncogene 13:177-181, 1996). In the present work we first study 12 BL patients and show that the virus strain in the tumor is identical in EBNA1 sequence and that it is matched at several other polymorphic loci to the dominant strain rescued in vitro from the patient's normal circulating B cells. We then analyze BL-associated virus strains from three different geographic areas (East Africa, Europe, and New Guinea) alongside virus isolates from geographically matched control donors by using sequence changes in two separate regions of the EBNA1 gene (N-terminal codons 1 to 60 and C-terminal codons 460 to 510) to identify the EBNA1 subtype of each virus. Different geographic areas displayed different spectra of EBNA1 subtypes, with only limited overlap between them; even type 2 virus strains, which tended to be more homogeneous than their type 1 counterparts, showed geographic differences at the EBNA1 locus. Most importantly, within any one area the EBNA1 subtypes associated with BL were also found to be prevalent in the general population. We therefore find no evidence that Burkitt lymphomagenesis involves a selection for EBV strains with particular EBNA1 sequence changes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882297      PMCID: PMC103916     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.

Authors:  M N Wrightham; J P Stewart; N J Janjua; S D Pepper; C Sample; C M Rooney; J R Arrand
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

2.  Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus.

Authors:  S N Li; Y S Chang; S T Liu
Journal:  Oncogene       Date:  1996-05-16       Impact factor: 9.867

3.  Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA.

Authors:  A Bochkarev; J A Barwell; R A Pfuetzner; E Bochkareva; L Frappier; A M Edwards
Journal:  Cell       Date:  1996-03-08       Impact factor: 41.582

4.  Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1.

Authors:  A Bochkarev; J A Barwell; R A Pfuetzner; W Furey; A M Edwards; L Frappier
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

5.  Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; D Dukers; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice.

Authors:  J B Wilson; J L Bell; A J Levine
Journal:  EMBO J       Date:  1996-06-17       Impact factor: 11.598

7.  Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas.

Authors:  K Bhatia; A Raj; M I Guitierrez; J G Judde; G Spangler; H Venkatesh; I T Magrath
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

8.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

9.  Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene.

Authors:  P Busson; R H Edwards; T Tursz; N Raab-Traub
Journal:  J Gen Virol       Date:  1995-01       Impact factor: 3.891

10.  Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders.

Authors:  V Schuster; G Ott; S Seidenspinner; H W Kreth
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

View more
  29 in total

1.  EBNA-1 sequences in endemic and sporadic Burkitt's lymphoma.

Authors:  K Bhatia; I Magrath
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Novel intertypic recombinants of epstein-barr virus in the chinese population.

Authors:  R S Midgley; N W Blake; Q Y Yao; D Croom-Carter; S T Cheung; S F Leung; A T Chan; P J Johnson; D Huang; A B Rickinson; S P Lee
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 3.  Molecular evolution of the gamma-Herpesvirinae.

Authors:  D J McGeoch
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

4.  Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

Authors:  J M Brooks; D S Croom-Carter; A M Leese; R J Tierney; G Habeshaw; A B Rickinson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.

Authors:  Mei Hong; Yoshihiro Murai; Tomohiko Kutsuna; Hiroyuki Takahashi; Kazuhiro Nomoto; Chun-Mei Cheng; Shin Ishizawa; Qing-Li Zhao; Ryohei Ogawa; Brian V Harmon; Koichi Tsuneyama; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-23       Impact factor: 4.553

6.  Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.

Authors:  Gemma L Kelly; Anne E Milner; Rosemary J Tierney; Debbie S G Croom-Carter; Markus Altmann; Wolfgang Hammerschmidt; Andrew I Bell; Alan B Rickinson
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Authors:  A Leen; P Meij; I Redchenko; J Middeldorp; E Bloemena; A Rickinson; N Blake
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation.

Authors:  R J Tierney; H E Kirby; J K Nagra; J Desmond; A I Bell; A B Rickinson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.

Authors:  Tawin Iempridee; Jessica A Reusch; Andrew Riching; Eric C Johannsen; Sinisa Dovat; Shannon C Kenney; Janet E Mertz
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1.

Authors:  Do Nguyen-Van; Ingemar Ernberg; Ingemar Enrberg; Phi Phan-Thi Phi; Chinh Tran-Thi; LiFu Hu
Journal:  Virus Genes       Date:  2008-07-29       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.